Related Experiment Video
Updated: Aug 14, 2025

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
Published on: July 25, 2025
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data
Manoj M Lalu1,2, Natasha Kekre1,3, Joshua Montroy1
1Centre for Practice-Changing Research, Office L1298a, Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road, Box 201B, Ottawa, Ontario, K1H 8L6, Canada.
Background:
Chimeric antigen receptor T cell therapy (CAR-T) represents a promising and exciting new therapy for hematologic malignancies, where prognosis for relapsed/refractory patients remains poor. Encouraging results from clinical trials have often been tempered by heterogeneity in response to treatment among patients, as well as safety concerns including cytokine release syndrome. The identification of specific patient or treatment-specific factors underlying this heterogeneity may provide the key to the long-term sustainability of this complex and expensive therapy. An individual patient data meta-analysis (IPMDA) may provide potential explanations for the high degree of heterogeneity. Therefore, our objective is to perform a systematic review and IPDMA of CAR-T cell therapy in patients with hematologic malignancies to explore potential effect modifiers of CAR-T cell therapy.
Methods And Analysis:
We will search MEDLINE, Embase, and the Cochrane Central Register of Controlled Clinical Trials. Studies will be screened in duplicate at the abstract level, then at the full-text level by two independent reviewers. We will include any prospective clinical trial of CAR-T cell therapy in patients with hematologic malignancies. Our primary outcome is complete response, while secondary outcomes of interest include overall response, progression-free survival, overall survival, and safety. IPD will be collected from each included trial and, in the case of missing data, corresponding authors/study sponsors will be contacted. Standard aggregate meta-analyses will be performed, followed by the IPD meta-analysis using a one-stage approach. A modified Institute of Health Economics tool will be used to evaluate the risk of bias of included studies.
Ethics And Dissemination:
Identifying characteristics that may act as modifiers of CAR-T cell efficacy is of paramount importance and can help shape future clinical trials in the field. Results from this study will be submitted for publication in a peer-reviewed scientific journal, presented at relevant conferences and shared with relevant stakeholders.
Insights
This study systematically reviews chimeric antigen receptor T cell (CAR-T) therapy for blood cancers. It aims to identify patient and treatment factors influencing CAR-T efficacy and safety in relapsed/refractory patients.
Area of Science:
- Hematologic Oncology
- Immunotherapy
- Clinical Trials
Background:
- Chimeric antigen receptor T cell (CAR-T) therapy shows promise for hematologic malignancies but faces challenges with treatment response heterogeneity and safety concerns like cytokine release syndrome.
- Identifying factors influencing CAR-T efficacy is crucial for the long-term sustainability of this complex therapy.
- Individual patient data meta-analysis (IPDMA) can help explain response variability.
Purpose of the Study:
- To conduct a systematic review and IPDMA of CAR-T cell therapy in patients with hematologic malignancies.
- To explore potential patient- or treatment-specific factors that modify CAR-T cell therapy efficacy and safety.
Main Methods:
- Systematic literature search of MEDLINE, Embase, and Cochrane Central Register of Controlled Clinical Trials.
- Inclusion of prospective clinical trials of CAR-T therapy in hematologic malignancies, with duplicate screening and data extraction.
- Primary outcome: complete response. Secondary outcomes: overall response, progression-free survival, overall survival, and safety. IPD meta-analysis using a one-stage approach.
Main Results:
- This section is to be filled after the study is conducted.
Conclusions:
- Identifying modifiers of CAR-T cell efficacy is paramount for optimizing future clinical trials.
- Results will inform the development of more personalized and effective CAR-T treatment strategies.
- Findings will be disseminated through peer-reviewed publications, conferences, and stakeholder engagement.
Related Concept Videos
Tumor Immunotherapy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

